Past Coverage of ACR 2016Past Coverage of ACR 2016 Return To RheumReports Home
At today's ACR Concurrent Abstract Session, new options for PsA treatment were presented, with encouraging results for a growing selection of therapeutic options.
First, Dr. Mease presented the 52-week data from the Phase 3 SPIRIT P1 study on Ixekizumab (IXE), a monoclonal antibody against IL-17A. It was an RCT with 4 arms; placebo, IXE 80 mg q2weeks or q4weeks, or adalimumab 40 mg. Results showed efficacy in ACR scores, HAQ DI, DAS 28 CRP, PASI 75/90/100, LEI and LDI-B. The skin, dactylitis and enthesitis scores were particularly impressive. There were no new safety signals with low overall SAEs and no deaths.
Dr. Mease also presented the 3-year extension data from FUTURE 1 that evaluated Secukinumab in PsA. This trial represents the longest period of observation to date with an IL-17 inhibitor. The RCT included an IV loading dose followed by either 75 or 150 mg sc q4weeks. 457 patients continued to 156 weeks. The results confirm the efficacy of both doses in all outcomes assessed and in both TNFi-naïve and in patients with prior TNFi exposure, although better ACR scores were reported in the naïve population in general (as expected). The drug was well tolerated with no unexpected side effects. There were a few candidal skin infections and a low number of Crohn's disease flares.
There is more research that will be presented at this meeting on Abatacept and Tofacitinib; the options for PsA continue to grow!
Share This Report
About the Author
Dr. Shelly Dunne
Dr. Shelley Dunne is a graduate of Memorial University of Newfoundland School of Medicine. She completed her training in Internal Medicine and a fellowship in Rheumatology at the University of Toronto. She has been in private practice since 1998 and is currently a consulting rheumatologist at the Toronto East General Hospital.
View Full Bio